Clinical studies have demonstrated that SGLT2 inhibitors improve cardiac [3, 4] and renal outcomes [5] in diabetic and non-diabetic conditions, including CKD [6, 7] and heart failure [8]. Here, SLC5A2 is linked to chronic kidney disease.